ReviewJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2013
Regadenoson: a focused update.
Review in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Pooled it
- Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Trial
- Differences in coronary microcirculation measurements during regadenoson vs. adenosine - induced hyperemia.Cardiology journal · 2025Article
- Exploring the untapped pharmacological potential of imidazopyridazines.RSC advances · 2024Review
- Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.Molecular diversity · 2022Review
- Prognostic value of absent left ventricular ejection fraction reserve with regadenoson SPECT MPI.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Comparative efficacy and safety of adenosine and regadenoson for assessment of fractional flow reserve: A systematic review and meta-analysis.World journal of cardiology · 2022Article
- Agonist-Dependent Coupling of the Promiscuous Adenosine AACS pharmacology & translational science · 2022Article
- Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.Nature reviews. Nephrology · 2020Review
- Diagnostic Approach to Patients with Stable Angina and No Obstructive Coronary Arteries.European cardiology · 2019Review
- Safer stress tests for myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Myocardial CT perfusion imaging for ischemia detection.Cardiovascular diagnosis and therapy · 2017Review
- A helping hand for regadenoson tests.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- The prognostic value of regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Article
- Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Review
- Quantification of myocardial perfusion in clinical trials.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Article
- Direct myocardial ischemia imaging: a new cardiovascular nuclear imaging paradigm.Clinical cardiology · 2015Review
- Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.International journal of chronic obstructive pulmonary disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its approval by the Food and Drug Administration in 2008, regadenoson has become the most commonly used vasodilator in the United States. Previous reviews have summarized the pre-clinical and clinical data on the use of regadenoson for myocardial perfusion imaging (MPI). Since then, data have emerged on the safety of this agent in special groups of patients such as those with chronic kidney disease, airway disease (asthma and chronic obstructive pulmonary disease), and liver disease. There has also been recent interest in the use of regadenoson in hybrid protocols with exercise as a way to improve patient tolerance and image quality. Finally, although regadenoson was approved for clinical use based on the agreement rate of regadenoson MPI and adenosine MPI with regards to perfusion abnormalities, data are now available on the prognostic data derived from regadenoson MPI. We will briefly summarize these recent reports here in a focused update on the use of regadenoson for MPI.
Indexed as
Identifiers
23229649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.